EULAR 2024

IL-17 inhibition & new molecules

Subclinical PsA - where is the border?

Tyk2 inhibition in PsA - a new opportunity?

Difference in axial involvement in axSpA and axPsA

Handling cardiovascular risks in RA

Tapering or even stopping TNF inhibitors in pts. with sustained remission?!

Deeper B-cell depletion

JAK inhibitors in GCA - a good opportunity?

Neuroinflammation as possible cause of intestinal dysbiosis in axSpA

Uterine inflammation in the pathogenesis in axSpA

What advances the radiographic progression? IL-17A vs. TNF inhibition

Sooner or later - when therapy with biologics?

Treat-to-target in axSpA - a long way to go!

Factors associated with spinal progression in axSpA

Avoiding overdiagnosis in axSpA

Minimal spinal radiographic progression with Bimekizumab

Treat-to-target approach to induce sustained clinical remission in early axSpA

Was treibt die Röntgenprogression an? IL-17A vs. TNF Inhibition

Früher oder später - wann Therapie mit Biologika?

Ruolo della neuroinfiammazione della patogensi dell’AxSpA

Vermeidung von Überdiagnose bei axSpA

Minimale Röntgenprogression der Wirbelsäule unter Bimekizumab

Approccio treat-to-target per indurre una remissione clinica sostenuto in early axSpA

Treat-to-target bei der axSpA - a long way to go!

Ruolo dell’infiammazione uterina nella patogenesi dell’axSpA

Subclinical PsA - where is the border?

Difference in axial involvement in axSpA and axPsA

Tyk2 inhibition in PsA - a new opportunity?

IL-17 inhibition & new molecules

A mouse model for PsA and PsO!

A lot of steroids always help - no matter the concomitant medication...

Early prediction by FAPI-PET in PsA

12-weeks results from the PRO-SPIRIT study

Managing comorbidities in PsA

The difficult cases in PsA

Cardiovascular outcome in PsA - TnF vs. IL-17 inhibitors

Small molecules with a better enthesitis efficacy - new data on izokibep

Which treatment to prevent PsA from PsO?

Post-hoc analysis on severe disease activity in PsA

Treatment strategy in early PsA - TnF inhibitors or not?

Sonelokimab, a new molecule for IL-17A & IL-17F inhibition - first data on arthritis

A new injection for knee osteoarthritis

The JAK family is growing. Another Tyk2 inhibitor: safe - with a moderate effect

Rhumatisme psoriasique débutant : anti TNF ou pas?

Die JAK-Familie wächst. Ein weiterer Tyk2-Inhibitor: sicher - mit moderatem Effekt

Risque cardiovasculaire et rhumatisme psoriasique : anti TNF ou anti Interleukine 17?

Risultati a 12 settimane dello studio di Real World "PRO-SPIRIT"

Viel Kortison hilft immer - Begleittherapie egal...

Valutazione della risposta a due anni di trattamento nei pazienti con Artrite Psoriasica con elevata attività di malattia

Kleine Moleküle mit besserer Enthesitiswirkung - neue Daten zu Izokibep

Sonelokimab, ein neues Molekül zur IL-17A- & IL-17F-Inhibition - erste Daten zur Arthritis

Quel traitement pour prévenir l’évolution du psoriasis vers un rhumatisme psoriasique?

Frühe Prädiktion durch FAPI-PET bei PsA

JAK inhibitors in GCA - a good opportunity?

Handling cardiovascular risks in RA

Deeper B-cell depletion

Tapering or even stopping TNF inhibitors in pts. with sustained remission?!

ARCTIC REWIND - Tapering not recommended in patients on TNF inhibitors in stable remission

No new safety signals from the JAK-POT study

Real-world data on safety of etanercept biosimilar

A model to predict progression from palindromic rheumatism to persistent arthritis

Tapering of TNF Inhibitors in RA Patients with sustained Remission

New JAK inhibitor tested in a Phase III trial in China

Abatacept vs adalimumab in dual seropositive RA patients with the shared epitope

Debate on regulatory safety measures for JAKies based on ORAL Surveillance study

Statins in RA - who benefits?

Good news in RA

Anti-citrullinated protein antibody (ACPA) does not predict response to abatacept in RA

Debate on therapeutic drug monitoring

Potential new treatment class in RA

Statine bei der RA - wer profitiert?

ARCTIC REWIND – dosereduksjon og seponering anbefales ikke hos pasienter i stabil remisjon under behandling med en TNF-hemmer

Debatt om bruk av therapeutic drug monitoring (TDM, monitorering av legemiddelkonsentrasjoner) i klinisk praksis

Reducción y suspensión de los inhibidores del TNF en pacientes con AR en remisión mantenida

Keine neuen Safety-Signale aus der JAK-POT Studie

Abatacept vs adalimumab en pacientes con AR doble seropositivos con el epitopo compartido

Un modelo para predecir la progresión del reumatismo palindrómico a artritis persistente

En ny JAK hemmer undersøkt i en fase III studie I Kina

Debatt om regulatoriske krav om sikkerhet ved bruk av JAK hemmere basert på den publiserte ORAL Surveillance study

Upadacitinib in GCA

Upadacitinib bei RZA

The role of rheumatoid factor from early to late

AI in rheumatology

Holistic view on multidisciplinary care in rheumatology

Daratumumab in SLE

How to treat Lupus: What's on the horizon?

Daratumumab bei SLE